Related Experiment Videos
Association between calcium channel blockers and gingival hyperplasia
Gaganpreet Kaur1, Katia M C Verhamme, Jeanne P Dieleman
1Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Journal of Clinical Periodontology
|July 21, 2010
Summary
Calcium channel blockers (CCBs) significantly increase gingival hyperplasia risk, especially dihydropyridines and benzothiazepines. Higher doses and shorter use durations further elevate this risk.
Area of Science:
- Pharmacology
- Oral Medicine
- Cardiovascular Therapeutics
Background:
- Gingival hyperplasia is a known side effect of certain medications.
- Calcium channel blockers (CCBs) are widely prescribed for cardiovascular conditions.
- Understanding the specific risks associated with CCB use is crucial for patient safety.
Purpose of the Study:
- To investigate the association between calcium channel blockers (CCBs) and gingival hyperplasia.
- To determine if the risk of gingival hyperplasia varies by CCB type and dosage.
- To quantify the risk of gingival hyperplasia in CCB users compared to renin-angiotensin system (RAS) drug users.
Main Methods:
- A nested case-control study was conducted within a large primary care database.
- Cases were patients with validated gingival hyperplasia diagnoses.
- Controls were matched for age, gender, and index date, comparing CCB users to RAS drug users.
Main Results:
- A higher risk of gingival hyperplasia was observed in current CCB users (OR(adj) 2.2).
- Dihydropyridines and benzothiazepine derivatives showed increased risk (OR(adj) 2.1 and 2.9, respectively).
- Risk escalated with higher-than-recommended doses (OR(adj) 3.0) and short-term use (<1 month, OR(adj) 5.2).
Conclusions:
- CCB use is associated with a twofold higher risk of gingival hyperplasia compared to RAS drugs.
- The risk is dose-dependent and particularly pronounced with dihydropyridine and benzothiazepine CCBs.
- Short-term, high-dose CCB use warrants careful monitoring for gingival hyperplasia.
Related Concept Videos
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...